Chemexpress(SH:688131)2025-01-24 10:15Financial Projections - The company expects 2024 annual revenue to be between RMB 210 million and RMB 230 million, representing a year-on-year increase of RMB 21.99 million to RMB 41.99 million, or a growth of 11.70% to 22.34%[4] - The projected net profit attributable to shareholders for 2024 is expected to be between RMB 185 million and RMB 210 million, an increase of RMB 57.55 million to RMB 82.55 million, translating to a growth of 45.16% to 64.77% compared to the previous year[4] - The anticipated net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is expected to be between RMB 165 million and RMB 190 million, reflecting a year-on-year increase of RMB 54.87 million to RMB 79.87 million, or a growth of 49.83% to 72.53%[4] - In 2023, the company achieved a revenue of RMB 188 million and a net profit of RMB 127.44 million[5] - The performance forecast is based on preliminary calculations and has not yet been audited by certified public accountants[8] - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the 2024 annual report[9] Strategic Focus - The company emphasizes a strategic focus on "industrialization, globalization, and branding," aiming for stable growth through innovation and market expansion[7] - The high-margin life science reagent business has shown strong growth, with an increased revenue share compared to 2023, focusing on early-stage drug discovery and providing diverse product and technical support[7] - The company is implementing measures to enhance operational efficiency, control costs, and improve cash flow management, contributing to the overall profit growth[7]